Prima BioMed Announces Immutep's IMP321 Patent Application Receives Canadian Patent Office Notice of Grant
Marketwired - Mon Dec 22, 6:10AM CST
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company"
PBMD: 0.75 (-0.05)
Prima BioMed Completes Immutep Acquisition
Marketwired - Wed Dec 17, 7:25AM CST
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima" or the "Company"
PBMD: 0.75 (-0.05)
Prima Biomed Enhances CVac Manufacturing and Logistics Capability
Marketwired - Fri Dec 05, 6:55AM CST
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima", the "Company"
PBMD: 0.75 (-0.05)
CVac Demonstrates Overall Survival Benefit in Second Remission Ovarian Cancer
Marketwired - Thu Nov 06, 6:45AM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.75 (-0.05)
Prima BioMed to Host Conference Call & Webcast to Discuss Acquisition of Immutep
Marketwired - Tue Oct 21, 10:15AM CDT
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima" or "the Company"
PBMD: 0.75 (-0.05)
Prima BioMed announces Notice of Allowance for LAG-3 Ig (IMP321) in Australia
M2 - Wed Oct 15, 6:47AM CDT
Immunocellular therapeutic company Prima BioMed (ASX
PBMD: 0.75 (-0.05)
Prima Announces Immutep's IMP321 Patent Application Receives Australian Notice of Allowance
Marketwired - Tue Oct 14, 7:45AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company"
PBMD: 0.75 (-0.05)
Prima Secures US$37.4M Investment Agreement With US Institutional Investor Bergen
Marketwire - Thu Oct 02, 6:01AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.75 (-0.05)
Prima BioMed Announces Strategic Acquisition of Immutep SA
Marketwire - Thu Oct 02, 6:00AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD)
PBMD: 0.75 (-0.05)
CVac(TM) CAN-003 Abstract Accepted For Poster Presentation At The Society For Immunotherapy Of Cancer Annual Meeting
PR Newswire - Tue Aug 19, 8:52AM CDT
Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ("Prima", the "Company"
PBMD: 0.75 (-0.05)
Prima Receives wins US patent for its personalised immunotherapy CVac
M2 - Thu Jul 17, 7:32AM CDT
Immunocellular therapeutic company Prima BioMed (ASX
PBMD: 0.75 (-0.05)
Prima Receives US Patent Grant for CVac
Marketwire - Wed Jul 16, 7:20AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company"
PBMD: 0.75 (-0.05)
Prima BioMed names Marc Voigt as CEO
M2 - Wed Jul 09, 5:33AM CDT
The board of Prima BioMed (ASX
PBMD: 0.75 (-0.05)
Prima BioMed Appoints New Chief Executive Officer
Marketwire - Wed Jul 09, 2:59AM CDT
The Board of Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company"
PBMD: 0.75 (-0.05)
Prima BioMed's CAN-002 CVac(TM) Trial Published in Journal for ImmunoTherapy of Cancer
Marketwire - Mon Jun 23, 7:52AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company"
PBMD: 0.75 (-0.05)
Prima BioMed to Present at 2014 WAGO Annual Meeting
Marketwire - Thu Jun 19, 7:20AM CDT
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company"
PBMD: 0.75 (-0.05)
Global Psoriasis Drug Forecast and Market Analysis to 2022 - Sales by region
M2 - Thu Feb 27, 2:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/bkkwwm/pharmapoint) has announced the addition of the "PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2022" report to their offering. 2012 PsO drug sales to be $5.6 billion across the nine major markets (9MM) covered in this report: US, France, Germany, Italy, Spain, UK, Japan, China, and India. By forecast end in 2022, sales will increase to over $7.62 billion at a Compound Annual Growth Rate (CAGR) of 3.1%, which includes seven pipeline therapies and the launch of biosimilars. This growth will be driven by: - The launch of novel PsO products, such as Eli Lilly's ixekizumab, Amgen's brodalumab, Novartis' secukinumab, Merck's MK-3222, Pfizer's Xeljanz (tofacitinib), Celgene's apremilast, and Biocon's Alzumab (itolizumab) - The uptake of biosimilars for the currently marketed biologics: etanercept, adalimumab, infliximab, and ustekinumab - Increased access to PsO biologics in China and India Despite these drivers, the PsO market will be crowded, yet comprised of diversified therapies. Individual drugs will struggle to gain a foothold as they distinguish themselves from each other. Unmet Needs in Psoriasis While dermatologists agree that the current biologics have revolutionized the PsO landscape, there is a dire need for therapies that can provide long-lasting effects, without side effects or an increased risk of comorbidities. The current pipeline includes at least four novel therapies that have exceptionally high clinical efficacy and good safety profiles, and these include: Novartis' secukinumab, Amgen's brodalumab, Merck's MK-3222, and Eli Lilly's ixekizumab. The dosing schedule for these therapies is quite convenient, as some of them are dosed once monthly and four times a year on average. Interestingly, of the seven pipeline products, three are me-too biologics, each of which targets the cytokine interleukin-17 (IL-17). However, we expect Novartis' inhibitor to be the first of this group to launch in 2014. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Amgen - AbbVie (Abbott) - Johnson & Johnson - Novartis - Pfizer - Eli Lilly - Merck - LEO Pharma - Celgene For more information visit http://www.researchandmarkets.com/research/bk...harmapoint
JNJ: 104.59 (+0.31), PBMD: 0.75 (-0.05), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), NVS: 93.91 (+0.66), CELGZ: 3.34 (-0.01)
Pete A. Meyers to Join Prima BioMed's Board of Directors
Marketwire - Tue Feb 11, 5:45PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", the "Company"
PBMD: 0.75 (-0.05)
Source Exploration Corp. Announces Adoption of Advance Notice-By-Law and Retains Transcend Resource Group for Investor Relations Services
Marketwire Canada - Mon Feb 03, 12:52PM CST
Source Exploration Corp. (the "Corporation"
PBMD: 0.75 (-0.05), SOP.VN: 0.055 (-0.010)
Prima BioMed to Present at the 16th Annual BIO CEO & Investor Conference
Marketwire - Thu Jan 30, 8:20PM CST
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the Company"
PBMD: 0.75 (-0.05)